Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after
C Schönefeldt1, K Sockel, R Wehner
1Medical Clinic I, University Hospital Carl Gustav Carus, Dresden, Germany.
Blood Cancer Journal
|September 3, 2013
Abstract
No abstract available in PubMed .


